Conduent (NASDAQ:CNDT) Azioni

Conduent

Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.

Conduent Inc

TD Securities analyst Andrew Charles reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and maintains $31 price target.

News

Price Target

Reiteration

Analyst Ratings

JACK

TD Securities Reiterates Hold on Jack In The Box, Maintains $31 Price Target

Preliminary First Quarter Results
<ul>
<li>Comparable sales decreased by 2.6% from the prior-year period, with comparable sales in the North America region decreasing by 0.5%.</li>
<li>Net loss is expected to be $363 million, as compared with net income of $8 million in the corresponding prior-year period. On a non-GAAP basis, net loss is expected to be $6 million for the first quarter, as compared with net income of $21 million in the corresponding prior-year period.</li>
<li>First quarter loss per share is expected to be $3.81, as compared with earnings per share of $0.09 in the first quarter of 2024. Non-GAAP loss is expected to be $0.07 per share in the first quarter, as compared with non-GAAP earnings per share of $0.22 in the corresponding prior-year period.</li>
<li>Non-GAAP net loss and net loss per share exclude non-cash impairment charges totaling $276 million and primarily reflect a $140 million charge related to a&nbsp;tradename and a goodwill impairment charge of $110 million. Additionally, we recorded a full valuation allowance on the Company's deferred tax assets and deferred tax costs related to the Company's European business totaling $124 million, which is excluded from our non-GAAP results.</li>
</ul>

Earnings

Guidance

General

Foot Locker Reported Select Preliminary Financial Results For Its First Quarter 2025, With Non-GAAP EPS Of $(0.07) That May Not Be Comparable To Consensus Of $0.41

U.S. GoldMining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USGO#NASDAQ">USGO</a>) ("U.S. GoldMining" or the "Company") is pleased to provide an update on the results of exploration target delineation and analysis performed for the Whistler Gold-Copper Project (the "Whistler Project" or the "Project") in Alaska, U.S.A.
Highlights:
<ul>
<li>The Whistler Project lies within the emerging&nbsp;West Susitna Mineral District located just 100 miles west of Anchorage, Alaska.</li>
<li>The Company's 100% owned land package consists of 53,700 acres of State mining claims encompassing&nbsp;three separate gold ± copper ± silver mineral systems identified to date.
<ul>
<li>Whistler - Raintree mineral system – includes the Whistler and Raintree West deposits which are hosted within the broader Whistler Orbit intrusive center, comprising multiple additional mapped porphyry intrusions spread over an area of approximately 5 x 5 km, interpreted as a classic 'porphyry cluster' with potential for additional gold ± copper ± silver mineralization to be discovered. &nbsp;</li>
<li>Island Mountain mineral system – encompasses the known Island Mountain deposit plus several additional porphyry or intrusion related gold targets over an area of mapped intrusive rocks with diameter of +3 km.</li>
<li>Muddy Creek mineral system – a large gold-in-soil geochemical footprint over an area of approximately 6 km x 4 km with an intrusion-related gold geochemical signature.</li>
</ul>
</li>
<li>The Company is currently undertaking further analysis to rank and prioritize the numerous targets located across each of the three gold ± copper ± silver mineral systems identified to date, and to develop phased exploration programs which could commence this coming summer.</li>
</ul>

USGO

US GoldMining Maps Major Alaska Gold-Copper Targets Near Anchorage, Eyes Summer Drilling

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081350/BeiGene-900x600-1.png" alt="" class="wp-image-12984" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081350/BeiGene-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081350/BeiGene-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081350/BeiGene-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Global sales of the company's flagship drug for blood cancers rose 62% to $792 million in the first quarter, while U.S. sales reached $563 million</li>
<li>BeiGene is adopting a new English name, BeOne Medicines Ltd., and is moving its headquarters to Switzerland</li>
</ul>
One of China's leading makers of novel drugs, BeiGene Ltd. (688235.SH; 6160.HK; ONC.US), has arrived at a landmark on its earnings journey: its first quarterly profit.
That is, according to one widely accepted accounting measure. By another, it still has a few steps further to go. Investors have been eagerly tracking the company's progress towards the breakeven point, hoping that growing demand for BeiGene's blood cancer drugs would finally push its results definitively from the red into the black.
First-quarter&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0507/2025050701562.pdf">earnings</a>&nbsp;prepared under GAAP accounting rules for release in the U.S. market crossed that threshold into net profit, although the figures issued in China showed a lingering bottom-line loss despite a swing into operating profit.
The company publishes results in the three jurisdictions in which it is listed: Hong Kong, the United States and mainland China.&nbsp; On May 7 it announced a first-quarter net profit of $1.27 million (9.19 million yuan) on a GAAP basis, compared with a net loss of $251 million during the same period of 2024. Meanwhile, applying another accounting method for China, the company moved into operating profit and shank its net loss to 95 million yuan from 1.91 billion yuan in the same period last year.
The earnings spurt was driven by strong sales of its flagship oncology drugs. Product revenue rose 47% to $1.1 billion in the first quarter of 2025. Zanubrutinib, sold under the U.S. brand name Brukinsa, accounted for 70% of product sales. Demand for the kinase inhibitor, which blocks growth-related proteins in cancers affecting white blood cells, has been booming since U.S. regulators approved the drug to treat chronic lymphocytic leukemia and other cancers.
Zanubrutinib went on to achieve blockbuster status after breaching the $1 billion annual sales barrier in 2023.
Also driving the latest earnings are the PD-1 antibody drug tislelizumab and products licensed in from Amgen, BeiGene said.
Zanubrutinib sales jumped 62% to $792 million in the first quarter from the equivalent period of 2024, with $563 million in the United States alone. Expanded use among patients with chronic lymphocytic leukemia explains more than 60% of its quarter-on-quarter sales growth. Sales surpassed those of a competing drug co-developed by Johnson &amp; Johnson and AbbVie, ibrutinib, making BeiGene's product the market leader in the U.S. BTK inhibitor market. Meanwhile, sales in Europe surged 73% to $116 million on increased market penetration in Germany, Italy, Spain and France.
Sales of tislelizumab, which helps the immune system attack tumor cells, rose 18% to $171 million, outpacing equivalent drugs from Chinese drug companies after making inroads into overseas markets. The drug, which is marketed under the brand name Tevimbra, has been approved in 46 markets and was recently included in medical insurance schemes in the U.S., Europe and China.
<h4 class="wp-block-heading">Going for global impact</h4>
The overseas market is critical for the company, whose globalization strategy is gathering pace just as tensions are ratcheting up between China and the United States. Its original logo featured traditional Chinese calligraphy, but the company took on the English name BeiGene when it went public in 2021. It announced plans for another name change to BeOne Medicines Ltd. in November 2024, and said in its latest results that it would move its headquarters to Switzerland.
Pharmaceuticals are currently exempted from U.S. tariffs, but President Donald Trump has said medicines could be subject to new levies. U.S. production of the two BeiGene flagship drugs is all carried out by a U.S.-based partner with very limited involvement by Chinese suppliers. Thus, any tariffs targeting medical products are likely to have limited impact on the company, which inaugurated a new hub on the Princeton West Innovation Campus in Hopewell, New Jersey, in July last year. The base is equipped with world-class facilities to manufacture biologics as well as to conduct clinical research.
In European and U.S. markets, BeiGene cut sales expenses as a share of product revenue to 41% in the first quarter from 57% in the same period of 2024. The fact that rapidly rising revenue was accompanied by a mere 7% increase in sales and management expenses to $888 million points to improved operating efficiency.
The company has a lot riding on another potentially lucrative drug that targets a protein linked to cell growth. Its drug sonrotoclax, a BCL2 inhibitor, is aimed mainly at hematological tumors.
A marketing application for the drug has been filed in China and is being reviewed on a priority basis, while U.S. regulators have also granted the product fast-track status for use among patients with mantle cell lymphoma and a rare type of blood cancer.
The company currently trades at a price-to-sales (P/S) ratio of around 5.6 times in Hong Kong, compared with 6.6 times for&nbsp;Shanghai Junshi Biosciences&nbsp;(688180.SH; 1877.HK) which also sells PD-1 drugs overseas. As BeiGene starts to deliver profits and improve its operating cash flow, shareholders may enjoy a greater payback.

Equities

WIIM

Opinion

Trading Ideas

Market Shrugs Off This Drugmaker's Turnaround

Preliminary First Quarter Results
<ul>
<li>Comparable sales growth of 4.5%</li>
<li>Earnings per diluted share of $3.24 and non-GAAP earnings per diluted share of $3.37</li>
</ul>

DICK'S Sporting Goods Reported Select Preliminary Financial Results For Its First Quarter 2025, With EPS Of $3.24 And non-GAAP EPS Of $3.37 Vs. Consensus Of $3.22

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly owned subsidiary focused on commercializing OST-HER2 for the treatment of canine osteosarcoma.
<ul>
<li>OST-HER2 market opportunity in canine osteosarcoma exceeds $150 million</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fos-therapies-announces-positive-data-114200323.html&amp;esheet=54255443&amp;newsitemid=20250515280996&amp;lan=en-US&amp;anchor=Recent+data+in+prevention+of+amputation+in+frontline+canine+osteosarcoma+and+control+of+metastatic+osteosarcoma+adds+to+historical+data+that+supported+prior+conditional+approval+related+to+increase+in+overall+survival+%28OS%29+post-amputation&amp;index=1&amp;md5=a3055be596dfad558e9efcc58ab222ef">Recent data in prevention of amputation in frontline canine osteosarcoma and control of metastatic osteosarcoma adds to historical data that supported prior conditional approval related to increase in overall survival (OS) post-amputation</a></li>
<li>Updated commercial manufacturing process to be used in pending new USDA conditional approval application for frontline, metastatic and OS in osteosarcoma</li>
</ul>
OST-HER2 is an off-the-shelf immunotherapy candidate that has shown positive clinical data in both human pediatric and canine osteosarcoma. Parent company OS Therapies is advancing towards an FDA Accelerated Approval submission, anticipated in the third quarter of 2025, for the prevention of recurrence in pediatric patients with fully resected, lung-metastatic osteosarcoma. Concurrently, its wholly-owned subsidiary, OS Animal Health, is focused on re-establishing USDA conditional approval for OST-HER2 in canine osteosarcoma, with a targeted submission in the second half of 2025.

OSTX

OS Therapies Launches Animal Health Arm to Tackle Dog Bone Cancer With $150M Market Potential

NACG's outlook for 2025
The following table provides projected key measures for 2025. These measures are predicated on contracts currently in place, including expected renewals, and the heavy equipment fleet that we own and operate.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Key measures</td>
<td>2025</td>
</tr>
<tr>
<td>Combined revenue(i)</td>
<td>$1.4 - $1.6B</td>
</tr>
<tr>
<td>Adjusted EBITDA(i)</td>
<td>$415 - $445M</td>
</tr>
<tr>
<td>Sustaining capital(i)</td>
<td>$180 - $200M</td>
</tr>
<tr>
<td>Adjusted EPS(i)</td>
<td>$3.70 - $4.00</td>
</tr>
<tr>
<td>Free cash flow(i)</td>
<td>$130 - $150M</td>
</tr>
<tr>
<td>Capital allocation</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Growth spending(i)</td>
<td>$65 - $75M</td>
</tr>
<tr>
<td>Net debt leverage(i)</td>
<td>Targeting 1.7x</td>
</tr>
</tbody>
</table>
</figure>

TSX:NOA

CORRECTION: North American Construction Reaffirms FY25 Outlook: Adj EPS CAD 3.70 - CAD 4.00, Combined Revenue CAD 1.40B - CAD 1.60B

During the pre-market trading session on Thursday, Occidental Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) fell 2.56%, Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) declined 2.39%, while Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) fell 1.50% as oil prices saw a considerable drop. This decline is attributed to the potential U.S.-Iran nuclear deal and a sudden increase in U.S. crude oil inventories, triggering concerns of oversupply.
What Happened: Oil prices plunged by more than $2, spurred by the prospects of a nuclear deal between the U.S. and Iran that could result in relaxed sanctions. At the same time, an unexpected rise in U.S. crude oil inventories last week has intensified oversupply worries. U.S. crude oil inventories rose by 3.5 million barrels to 441.8 million last week, contrary to analysts&#8217; expectations of a 1.1 million-barrel decrease, according to the Energy Information Administration, reported Reuters.
Brent crude futures fell $2.48, or 3.75%, to $63.61 a barrel, while U.S. West Texas Intermediate (WTI) crude futures dropped $2.66, or 4.18%, to $60.53 at 0920 GMT.
On Thursday, U.S. President Donald Trump announced that the U.S. was nearing a final agreement on a nuclear deal with Iran, stating that Tehran had &#8220;sort of&#8221; agreed to the terms. This came after an Iranian official told NBC News on Wednesday that Iran was prepared to make a deal with the U.S. if economic sanctions were lifted.
 John Evans, analyst at PVM Oil, stated, &#8220;The crude build in the EIA Inventory Report has chased down the prices, and the move is accelerated by what appears to be a cooling of animosity in the US/Iran nuclear negotiations.&#8221;
At the same time, the International Energy Agency raised its average oil demand growth forecast for 2025 to 740,000 barrels per day—an increase of 20,000 bpd from its previous report—citing stronger economic growth projections and lower oil prices as factors driving increased consumption.
SEE ALSO: <a href="https://benzinga.com/25/05/45427077/bitcoin-flat-ethereum-dogecoin-slip-analytics-firm-highlights-resurgence-in-btc-retail-interest-but-a-brief-pullback-might-be-close-by" target="_blank" rel="noreferrer noopener">Bitcoin Flat, Ethereum, Dogecoin Slip: Analyst Firm Sees &#8216;Significant Recovery&#8217; In Retail Interest But A Pullback Might Be Imminent &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fractional undi</a>
Why It Matters: Earlier this month, economist Peter Schiff <a href="https://www.benzinga.com/markets/commodities/25/05/45158813/trump-may-be-getting-lower-oil-prices-but-its-not-due-to-drill-baby-drill-peter-schiff-says-its-more-of-a-chill-baby-chill-scene-out-there">stated </a>that the decline in oil prices is less about a sudden market flood and more about a warning sign for a faltering global economy. 
He argued that oil prices are dropping as global trade is stalling and recession fears are throttling demand. This context provides a broader perspective on the current oil price situation, suggesting that larger economic factors are at play. 
Notably, the International Energy Agency (IEA) raised its average oil demand forecast for 2025 but expects global oil demand growth to slow to 650,000 barrels per day for the rest of the year, down from 990,000 bpd growth seen in the first quarter, due to economic challenges and record electric vehicle sales.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/markets/cryptocurrency/25/05/45426516/chuck-schumer-says-trump-is-letting-cartel-members-into-the-us-asks-how-much-memecoin-did-" target="_blank" rel="noreferrer noopener">Chuck Schumer Says Trump Is &#8216;Letting Cartel Members&#8217; Into The US, Asks How Much &#8216;Memecoin&#8217; Did They Pay</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Occidental Petroleum, ExxonMobil, Chevron Fall In Pre-Market As Oil Prices Plunge Amid Trump's US-Iran Nuclear Deal Comments

<a href="https://www.globenewswire.com/Tracker?data=ICCae7jhPFDYHi_UP90Phfw0lrApN3-4CSvlS2zThOEZi9meq0OfFE3L-TIzUcP_jiWdcqI3Sub0vp7VgmEGkmmGZm34QXcYubLaaWUpZDk=">Biodesix, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California.
The presentation titled "Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States" was presented yesterday by Kimberly Le, Biodesix Director of Health Economics and Outcomes Research at ISPOR 2025.
This study included over 350,000 patients with medical claims for lung nodules from 2015 through 2017. The results reinforce prior literature findings indicating that approximately two thirds of patients do not receive any clinical work-up after lung nodule discovery, and high rates of over- and under-treatment in those patients who do receive clinical work-up. Importantly, 60% of biopsies were performed on benign lung nodules and 35% of malignant nodules received a follow-up CT scan prior to diagnosis, suggesting the need for better methods to triage patients to expedite the appropriate course of treatment.
The presentation titled "Utilization of Proteomic Testing in Pulmonary Nodule Risk Stratification at a Safety-Net Hospital: An Observational Study" will be presented by Sonu Sahni, MD, Director of Lung Cancer Screening at Wyckoff Heights Medical Center in New York at the ATS 2025 Conference on Monday, May 19 at 2:30 pm ET.
This independent, single-center study characterizes the results of 103 patients who received Nodify Lung testing in real-world clinical practice at Wyckoff Heights Medical Center. The results highlight the role of Nodify Lung testing within a lung cancer screening program and the potential to guide management decisions through a high proportion of actionable results.

BDSX

Biodesix Highlights Urgent Need for Better Lung Nodule Diagnosis After Study of 350K U.S. Patients

T1 Energy Eyes Major Investment In Domestic Solar Supply Chain With New Saudi Partnership

Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) with a Buy and lowers the price target from $23 to $18.

ARTV

Needham Maintains Buy on Artiva Biotherapeutics, Lowers Price Target to $18

<a href="https://www.globenewswire.com/Tracker?data=VhmaZkWl3c2zEpI3Pcnd5ioMJYs_i6J4QQd8AkMa2Z4PMs7jsyPxRFF7GziL2sXe99kjbhyMJkpl7GoGBUBh3akdvdKuwJe-zGDlWqnFRk-1RXlZH2ULvuWiE9YzrUS4">Brand Engagement Network Inc. (BEN)</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>), an innovator in AI-powered customer engagement, announced it has entered into a formal agreement with <a href="https://www.globenewswire.com/Tracker?data=iGH81e772OiK1Lv1DVQclvq3Yy3PjeK2DVvnF2c1PfOMrHXce_6booRqFHov1Bs_xNVmdvFNV5eVeej2WFDV87ye2g4mYvrkmKtxVkNRL6sbRaWL7D09XBCBSRRiXfJM18UN2MZTQEaipmutRtf_SQ==">Seven Visions Resort &amp; Places, The Dvin</a> (The Dvin), to develop and deploy BEN's expert Concierge AI Agent at the iconic Yerevan destination. This collaboration signifies BEN's entry into the hospitality sector, which the parties believe will establish a new standard for AI-enhanced luxury guest experiences on a larger scale.
 &nbsp;
A Two-Phase Pilot Initiative Designed for Impact
The&nbsp;collaboration will begin with a two-phase pilot initiative, starting with a 24/7 Concierge AI Agent and following with a Reservation AI Agent. Both are powered by BEN's modular iSKYE platform, allowing clients to deploy high-impact use cases quickly and scale across&nbsp;the guest journey.&nbsp;
With this initiative, BEN enters the hospitality industry, offering secure, guest-first AI tailored for high-touch customer experience, marking a strategic expansion into a new vertical.
A Setting Built for Innovation
"Introducing AI at this level isn't just about adopting new technology—it's about redefining luxury," said Dvin owner Artak Tovmasyan, who also holds a 30% stake in a cybersecurity firm serving over 85% of Dubai's hotels. "We chose BEN for their secure, guest-first platform—designed with trust, speed, and world-class execution in mind."
"This is an opportunity to demonstrate the versatility of BEN's AI platform in a setting where service excellence is paramount," said Paul Chang, CEO of Brand Engagement Network.

BNAI

Brand Engagement Network Taps Hospitality Market With AI Concierge at The Dvin Resort

KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $3.21 billion which beat the analyst consensus estimate of $3.09 billion by 4.05 percent. This is a 41.75 percent increase over sales of $2.27 billion the same period last year.

Earnings Beats

BEKE

KE Holdings Q1 Adj. EPS $0.16, Inline, Sales $3.21B Beat $3.09B Estimate

T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. The company reported quarterly sales of $64.65 million which missed the analyst consensus estimate of $74.00 million by 12.64 percent.

Earnings Misses

T1 Energy Q1 EPS $(0.03) Beats $(0.07) Estimate, Sales $64.65M Miss $74.00M Estimate

North American Construction (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NOA#TSX">NOA</a>) reported quarterly earnings of $0.52 per share. This is a 34.18 percent decrease over earnings of $0.79 per share from the same period last year. The company reported $340.833 million in sales this quarter. This is a 14.75 percent increase over sales of $297.026 million the same period last year.

CORRECTION: North American Construction Q1 2025 Adj. EPS CAD 0.52 Down From CAD 0.79 YoY, Sales CAD 340.833M Up From CAD 297.026M YoY

<ul>
<li>Combination creates global platform within the growing sports retail industry, positioned to serve evolving needs of a broader range of consumers</li>
<li>Poised to drive long-term success through innovative store concepts and digital experiences</li>
<li>Foot Locker shareholders can elect to receive either $24.00 in cash or 0.1168&nbsp;shares of DICK'S Sporting Goods common stock for each share of Foot Locker common stock</li>
<li>Transaction expected to be accretive to DICK'S Sporting Goods EPS in the first full fiscal year post-close&nbsp;(excludes one-time costs)</li>
</ul>

DICK'S Sporting Goods Has Agreed To Acquire Foot Locker. This Transaction Implies An Equity Value Of Approximately $2.4B And An Enterprise Value Of Approximately $2.5B

Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) lowers FY2025 sales outlook from $7.30 billion-$8.30 billion to $6.10 billion-$7.10 billion vs $7.31 billion estimate.

CSIQ

Canadian Solar Lowers FY2025 Sales Guidance from $7.30B-$8.30B to $6.10B-$7.10B vs $7.31B Est

Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 1.39 percent. This is a 417.39 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $71.95 million which beat the analyst consensus estimate of $71.80 million by 0.20 percent. This is a 10.58 percent increase over sales of $65.06 million the same period last year.

KPLT

Katapult Holdings Q1 Adj. EPS $(0.73) Misses $(0.72) Estimate, Sales $71.95M Beat $71.80M Estimate

Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) sees Q2 sales of $91.000 million-$96.000 million.

XNET

Xunlei Sees Q2 Sales $91.000M-$96.000M

Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) sees Q2 sales of $1.900 billion-$2.100 billion vs $1.76 billion analyst estimate.

Comments

Conduent

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO